Might I be a candidate for a bit of T-maxxing?
Driven by internet trends and fatigue, I decided to test my testosterone levels—only to uncover the complicated science and hidden […]
Health
Heard on the Street: Heart disease remains humanity’s top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money
Heart disease remains humanity’s top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places
‘Very hot’ coffee and tea linked to higher cancer risk in nearly 1 million adults
NEWYou can now listen to Fox News articles! Regularly drinking very hot tea or coffee may raise the risk of
The double-cleanse shower, fans say, promises to clean skin while also nourishing it—and making you smell better, too.
Why washing your body once may no longer be good enough Source link
Here’s how to understand Oura ring sleep scores. Read more in this week’s WSJ Wellness newsletter.
People are going to great lengths to optimize their sleep. Plus, the boomers living with their parents in retirement communities
Son who lost father in 9/11 attacks shares powerful lessons 25 years later: ‘I’m still here’
NEWYou can now listen to Fox News articles! As the nation marks 25 years since Sept. 11, 2001, the weight
Ipsen Weighs U.S. Manufacturing Investment
The French drugmaker is considering building a U.S. production site, joining other European companies looking across the pond when planning
Chinese biotech companies are training their sights on one of the most lucrative medicines: GLP-1s
Long a maker of low-end generic drugs, the country is now home to biotech firms that are innovating fast. Source
Alcohol tied to surprising cancer death pattern in adults under 55, researchers find
NEWYou can now listen to Fox News articles! Annual U.S. cancer deaths tied to alcohol consumption more than doubled over
A new report shows 90% of major brand-name biologic drugs losing exclusivity over the next decade have no low-cost competitors in development
A new industry report shows 90% of major brand-name biologic drugs losing exclusivity over the next decade have no low-cost